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ABSTRACT 
 
Oxidative stress contributes to the pathogenesis of Duchenne muscular dystrophy 
(DMD). Although they have been used as a model for DMD, mdx mice exhibit a slowly 
developing cardiomyopathy. We hypothesized that the disease process was delayed 
owing to the development of an adaptive mechanism against oxidative stress, involving 
glutathione synthesis.  
At 15-20 weeks of age mdx mice displayed 33% increase in blood glutathione level 
compared to age-matched C57BL/6 mice. In contrast, cardiac glutathione content was 
similar in mdx and C57BL/6 mice, as a result in mdx mice heart of the balanced 
increased expression of glutamate cysteine ligase catalytic and regulatory subunits 
ensuring glutathione synthesis, and that of glutathione peroxidase-1 utilizing glutathione. 
Oral administration from 10 weeks of age of the glutamate cysteine ligase inhibitor, L-
buthionine(S,R)-sulfoximine (BSO, 5 mM), led to 33% and 50% drop in blood and cardiac 
glutathione, respectively, in 15-20-week-old mdx mice. Twenty-week-old BSO-treated 
mdx mice displayed left ventricular hypertrophy associated with diastolic dysfunction, 
discontinuities in beta-dystroglycan expression, micronecrosis and microangiopathic 
injuries. Examination of the glutathione status in 4 DMD patients provided evidence that 
3 of them displayed systemic glutathione deficiency. 
In conclusion, low glutathione resource hastens the onset of cardiomyopathy linked 
to a defect in dystrophin in mdx mice. This is relevant to the glutathione deficiency that 
DMD patients may suffer.  
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INTRODUCTION 
 
Duchenne muscular dystrophy (DMD) is a lethal X-linked recessive disorder due to a 
defect in dystrophin, a sub-sarcolemmal structural protein of the cardiac and skeletal 
muscles that contributes to the integrity of the cellular membrane.1 Dystrophin-deficient mdx 
mice are the most commonly used experimental model of DMD.2-7 In DMD patients, as well 
as in mdx mice, dystrophin defect alters the sarcolemmal integrity of cardiac and skeletal 
myocytes,8-10 with increased susceptibility to oxidative stress11-13 leading to necrotic cell 
death and inflammation.14, 15 Further evidence in support of oxidative stress as a cause of 
the dystrophic pathophysiology comes from in vivo studies demonstrating reduced signs of 
muscle damages in mdx mice given antioxidants.16, 17 
The tripeptide glutathione (L-gamma glutamyl-cysteinyl-glycine) is a major antioxidant, 
which plays a central role in cell redox regulation and controls multiple cellular processes. In 
particular, glutathione, through the inhibition of the neutral sphingomyelinase-dependent 
apoptotic pathway,18, 19 determines cardiac myocyte function and survival.20-22 Alterations in 
glutathione homeostasis and metabolism are associated with inflammation23 and 
characterize several human inflammatory chronic diseases.24, 25 Thus, fibroblasts from DMD 
patients show a low capacity for glutathione synthesis.26 In contrast, a noticeable feature of 
mdx mice dystrophic muscles is the up-regulation of glutathione peroxidase and glutathione 
reductase, which respectively utilizes and recycles reduced glutathione.27 However, this 
protective mechanism does not entirely compensate the chronic oxidative challenge since 
glutathione level in 6-8-week-old mdx mice tibialis anterior muscles is decreased by 20% 
compared to control mice.27 Accordingly, green tea polyphenols, which beyond their inherent 
antioxidant properties promote glutathione synthesis, reduce muscle damage and necrosis 
in mdx mice.16, 17 This does not rule out that the intrinsic increased turnover of glutathione in 
mdx mice may delay the progression of the dystrophic disease, although it cannot fully 
protect against it. 
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Cardiac manifestations of DMD are recognized later than those of skeletal muscles, 
but are present in 90% of DMD patients by the age of 18 years, progressing to fatal heart 
failure in 20% of patients.28 Similarly to DMD patients, mdx mice experience a progressive 
development of cardiac defects. However, the disease develops with less severity than in 
patients and in old mice only, young adult mice showing little echocardiographic signs of 
cardiomyopathy before 10 months of age.7, 29 Glutathione plays a central role in protecting 
cardiac vasculature,30 and cardiac glutathione deficiency is a common feature of 
cardiomyopathies in animal models20, 21 as in patients.21, 22, 31 
We hypothesized that the progression of cardiomyopathy in mdx mice was slow owing 
to a boost in glutathione synthesis and resource, set as an adaptation mechanism against 
oxidative stress. Mice administered oral L-buthionine sulfoximine (BSO), a specific inhibitor 
of glutamate cysteine ligase (GLCL), the rate-limiting enzyme of glutathione synthesis, are a 
suitable, well-characterized model for glutathione deficiency.32 From 10 weeks of age mdx 
mice experience a continuing cycle of skeletal muscle fiber degeneration and 
regeneration.33, 34 We chose this age to start a 10-week treatment with BSO added to the 
drinking water at a low dose (5 mM) devoid of toxicity.32 At variance from 20-week-old 
untreated mdx mice receiving water, 20-week-old BSO-treated mdx mice displayed cardiac 
left ventricular (LV) structural abnormalities and hypertrophy together with altered diastolic 
function, reminiscent of the early stage of the cardiomyopathy in DMD patients prior to the 
manifestations of clinical symptoms.35, 36 To get a first insight into the glutathione status of 
DMD patients, we measured blood glutathione in 4 DMD patients with mean age of 28 ± 2 
years and on wheelchair dependency. We found that 3 of them demonstrated systemic 
glutathione deficiency. 
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MATERIALS AND METHODS 
 
Patients  
This study, carried out prospectively for a period of 7 months (September 2009 to 
March 2010) at the AP-HP, Groupe Hospitalier Cochin, Service de Cardiologie, Paris, 
France and at the Hôpital Raymond Poincaré, Service de Réanimation et Unité de 
Ventilation à domicile, Garches) was conformed to the Declaration of Helsinki and to 
our institutional ethics committee. All the participants gave informed consent. We 
enrolled 4 consecutive patients with DMD, (4 males with mean age of 28 ± 2 years), 
referred to our institutions for cardiac evaluation. Patients underwent biological tests 
including the measurement of whole blood glutathione and an echocardiography (ATL 
HDI 5000 system, ATL Ultrasound, Bothell, WA). Examinations were conformed to the 
recommendations of the American Society of Echocardiography. Left ventricular 
ejection fraction (LVEF) was determined according to the Simpson’s method. Blood 
glutathione of DMD patients was compared to that of 4 matched healthy volunteers. 
 
Animals and experimental design 
Experimental procedures were performed in accordance with the European legislation 
on animal experimentation (L358-86/609/EEC). C57BL/6 (B6) and mdx4Cv (mdx) mice were 
used. The mdx4Cv mouse mutant, in which a C-to-T nucleotide transition generates a stop 
codon in exon 53 of the dystrophin gene, has almost no background of revertant fibers in 
skeletal muscle.4, 6, 37 B6 and mdx mice were randomly assigned to two groups: 1) an 
untreated group receiving water; 2) a group receiving L-buthionine sulfoximine (BSO, 
Sigma) via drinking water at the concentration of 5mM (average dose of 185 mg/kg/ day) 
from 10 to 20 weeks of age. As previously stated by Watanabe et al.,32 this dose of BSO did 
not produce either deaths or pathological signs. Blood was withdrawn from the queue at 
regular intervals from 3 weeks to 20 weeks of age. At 20 weeks of age, all mice were 
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subjected to echocardiography then euthanized by intraperitoneal injection of overdose 
anaesthetics (xyzaline (20 mg/kg) and ketamine (50 mg/kg). Blood was withdrawn and 
hearts were excised and frozen in liquid nitrogen cooled isopentane. All samples were 
stored at –80°C until use.   
 
Echocardiography 
Transthoracic 2D echocardiography measurements were performed in isoflurane-
anesthesied mice using an echocardiograph (Vivid 7, General Electric) equipped with a 
linear 13 MHz transducer. Body temperature was maintained with a heating pad. Numeric 
images were stored and reviewed at a slower frame rate by a single observator blinded of 
the animal treatment and genotype status. Left ventricle end-diastolic diameter (LVEDD), 
inter-ventricular septal wall thickness in diastole (IVS) and posterior wall thickness in 
diastole (LVPW) were measured from long axis view by two-dimensional-guided M-mode. 
LV mass (LVM) was calculated using the formula: LVM = 1.05 [(IVS + LVEDD + LVPW)3 - 
(LVID)3].38 Left ventricular ejection fraction (LVEF) was measured using two-D parasternal 
long axis cine-loop.39 Peak mitral early diastolic velocity (E), its deceleration time (DcT) and 
the peak velocity of the atrial contraction (A) were measured using the trans-mitral pulsed 
wave Doppler. All measurements were averaged on 3 consecutive cardiac cycles.  
 
Biochemical analysis 
Total glutathione was measured in patients and mice whole blood collected in EDTA 
tubes, and in mouse heart homogenates according to a modification of Tietze method40 as 
previously described.21, 22, 41 Results are given as means ± s.e.m of three separate 
determinations made in duplicates. 
 
Histological and immunohistochemical analysis 
Cardiomyocyte structure was studied in air-dried frozen heart sections from B6 mice, 
untreated or BSO-treated mdx mice. After blocking nonspecific staining with AffiniPure Fab 
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and Fc fragments (Jackson Immuno Research Laboratories),17 sections were incubated with 
either a mouse monoclonal antibody to β-dystroglycan (Abcam; diluted 1:50) and the 
secondary goat anti-mouse Alexa-fluor 555-conjugated antibody (Invitrogen; diluted 1:1000) 
or a rat monoclonal antibody to mouse CD68 (Serotec; diluted 1:250) and the biotinylated 
sheep secondary anti-rat IgG antibody (Serotec; diluted 1:500). Slides were mounted with 
Prolong Gold antifade reagent with DAPI (Invitrogen) or Immu-Mount (Thermo Electron 
Corporation) for β-dystroglycan or CD68 staining, respectively.  
 
Electronic microscopy 
Whole hearts were dissected and the apex of the LV was removed, and immediately 
placed in fix (4% paraformaldehyde, 3% glutaraldehyde in 0.1 M sodium phosphate buffer, 
pH 7.4) for 1h. The samples were transferred to 3% glutaraldehyde in phosphate buffer (0.1 
M sodium phosphate, pH 7.4) overnight, then washed for 15 min in phosphate buffer, and 
post-fixed for 1.5 h in phosphate buffer added with in 1% osmium tetraoxide. Following 
osmium fixation, the samples were rinsed 3 to 5 min in phosphate buffer, dehydrated for 10 
min in successive ethanol washes (50%, 70%, 80%, 95%, 100%, 100%), and rinsed for 15 
min in propylene oxide. Finally, the samples were embedded in Lowecryl resin, overnight. 
Sections of 70–80 nm were cut on a Reichert UltracutE, stained with 2% uranyl acetate plus 
Reynold’s lead citrate and viewed using a Phillips CM120 transmission electron microscope.  
 
RNA isolation and Real-Time PCR analysis  
Total RNA was extracted from frozen hearts using TRIzol reagent (Qiagen) and RT-
PCR was performed as previously described.42 Concentration of total RNA was dosed using 
a NanoDrop ND-1000 spectrophotometer (Labtech) and RNA quality was assessed by 
electrophoresis. cDNA was synthesized using  SuperScript III First-Strand Synthesis 
System for RT-PCR (Invitrogen). Real-time PCR was carried out on a Light Cycler (Roche 
Diagnostics), using the Quantitest SYBR green kit (Qiagen) with sense and anti-sense 
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oligonucleotides primers for the different genes (Table 1). The PCR-amplified products were 
controlled by sequencing. Relative levels of mRNA expression were calculated according to 
the ∆∆CT method. 43 Individual mRNA expression values were normalized by comparison 
with 18S mRNA level.  
 
Statistical analysis 
Data are expressed as means ± s.e.m. Data were analyzed by Mann-Whitney test or 
Kruskal-Wallis test combined with Dunn post-test, as appropriate (Prism, GraphPad 
Software Inc.). Echocardiographic measurements were analyzed by a two-way repeated 
measure ANOVA followed by a multiple comparison test (Holm-Sidak method). Statistical 
significance was assumed at p ≤ 0.05. 
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RESULTS 
 
Blood level and cardiac content of glutathione in mdx mice  
B6 mice displayed steady blood glutathione level from the age of 5 to 20 weeks, with 
an average value of 0.70 ± 0.03 mM. Until the age of 10 weeks, mdx mice had a similar 
blood glutathione level as B6 mice (Fig. 1). However, after 15 weeks of age, blood 
glutathione level in mdx mice increased by 33% to 0.93 ± 0.03 mM (Fig. 1). At variance from 
blood glutathione, cardiac glutathione content in 20-week-old mdx mice was not significantly 
increased as compared to B6 mice (Fig. 2), despite significant elevation in cardiac mRNA 
expression of both GLCL catalytic (GLCLC) and modulatory subunits (GLCLM) that ensure 
glutathione synthesis (Fig. 3). In fact, increased expression of GLCL subunits in the heart of 
20-week-old mdx mice coped with that of glutathione peroxidase-1 (GPx1) that utilizes 
glutathione to reduce hydroperoxides (Fig. 3). 
 
Effects of BSO treatment on blood and cardiac glutathione content in mdx mice  
BSO was given at a low non-toxic dose (5 mM), i.e. a dose that did not produce either 
deaths or pathological signs.32 BSO treatment, started at the age of 10 weeks, blunted the 
rise in blood glutathione level in 15- and 20-week-old mdx mice, maintaining it at 0.74 ± 0.04 
mM (Fig. 1). Cardiac glutathione content in BSO-treated mdx mice was decreased by 50% 
as compared to untreated mdx mice given water, reaching a level not significantly different 
from that in B6 mice, receiving water or BSO (Fig.2). The decrease in cardiac glutathione 
content in BSO-treated mdx mice was related to a reduced expression of glutathione 
enzyme mRNAs as compared to untreated mdx mice, similar to that in B6 mice (Fig. 3).  
 
BSO-treated mdx mice display LV hypertrophy and diastolic dysfunction  
As compared to age-matched B6 mice heart, 20-week-old mdx mice heart was 
featured by a smaller body weight-indexed LV mass (iLVM) related to thinner posterior and 
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intraventricular septal wall thickness (LVPW and IVS, respectively) (Fig.4A). In other ways, 
mdx mice displayed normal LV systolic function, assessed by the LV ejection fraction 
(LVEF), and normal LV diastolic function, assessed by both the ratio between early diastolic 
filling wave (E) and filling wave illustrating atrial contraction (A), and the E-wave deceleration 
time (DcT) (Fig.4A). Ten week BSO-treatment induced LV hypertrophy in mdx mice, as 
demonstrated by the 21% increase in iLVM (Fig.4A). LV hypertrophy in BSO-treated mdx 
mice had no impact on LV systolic function, but was associated with impaired diastolic 
function as characterized by a concomitant E/A decrease and DcT prolongation (Fig.4A). 
Noteworthy, LV hypertrophy in mdx mice was correlated with cardiac glutathione deficiency 
(r = 0.66, p = 0.002; Fig.4B).  
 
BSO-treated mdx mice display LV structure alterations 
Immunohistochemical analysis on LV sections of 20-week-old mdx mice given water 
showed a regular expression of beta-dystroglycan along cardiac myocyte membranes, 
similar to that in LV sections of age-matched B6 mice (Fig. 5A). LV of mdx mice receiving 
water did not present either any histologically discernable abnormality (as assessed by 
hematoxylin eosin staining, not shown), or fibrosis (assessed by red-sirius staining, not 
shown), despite increased gene expression of 1a2, 3a1 and 6a1collagens as compared to 
B6 mice (Fig. 5B). In contrast, LV of BSO-treated mdx mice displayed destabilized beta-
dystroglycan expression (Fig. 5A) with reduced collagen gene expression as compared to 
mdx mice receiving water (Fig. 5B). Foci of micronecrosis infiltrated by CD68+ 
macrophages (Fig. 6A and 6B) were also identified in LV sections of BSO-treated mdx 
mice.  
 
Electron microscopy reveals focal ultrastructural lesions in LV of BSO-treated 
mdx mice 
Electron microscopy analysis of LV of 20-week old mdx mice receiving water showed 
tightly packed contractile proteins, and did not show any ultrastructural abnormalities 
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(Fig.7A). In contrast, focal ultrastructural lesions were discernible in LV of BSO-treated mdx 
mice, with degenerative changes including intracellular amorphous accumulations 
separating contractile bundles, pronounced irregularities of sarcomere elements such as the 
Z-line (Z streaming), extreme dilation of smooth endoplasmic reticulum profiles and giant 
mitochondria (Figure 7B). These lesions were spatially associated with microangiopathic 
lesions characterized by edema in endothelial cells leading to partial obstruction of the 
lumen, and accompanied by edema in interstitium and neighboring cardiomyocytes (Fig. 8).  
 
Glutathione status in DMD patients 
Next, we intended to get a first insight into the glutathione status of DMD patients. 
Four DMD patients were enrolled, with mean age of 28 ± 2 years and on wheelchair 
dependency. They received an anti-angiotensin therapy, consisting in an angiotensin-
converting enzyme inhibitor or an angiotensin receptor blocker, and showed a mean 
LVEF of 45 ± 5%. Compared to healthy volunteers, 3 out of the 4 DMD patients 
displayed 25% to 40% deficiency in systemic glutathione (Fig.9). 
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DISCUSSION 
 
Our current findings are twofold. Firstly, the slow progression of cardiomyopathy in 
mdx mice is related to a boost in glutathione synthesis and resource. Conversely, 
administration of the GLCL inhibitor BSO to mdx mice from the age of 10 weeks leads to a 
decrease in glutathione resource in 20 week-old mdx mice, along with LV hypertrophy, 
diastolic dysfunction and structural alterations. Secondly, we point out the occurrence of 
glutathione deficiency in DMD patients.  
 Several studies have provided evidence that oxidative stress is implicated in the 
pathogenesis of the dystrophic disease in DMD patients13, 44-46 and mdx mice,12, 13 and that 
of cardiomyopathy in mdx mice.47 Oxidative stress in the dystrophic muscles of mdx mice is 
counteracted by compensatory mechanisms involving up-regulation of glutathione cycle 
enzymes.27, 45, 48 We now show a similar adaptation of glutathione cycle enzymes expression 
in the heart of mdx mice, together with increased systemic glutathione reserve from the age 
of 15 weeks, when mice undergo a continuing cycle of skeletal muscle fiber degeneration 
and regeneration.34, 49 Such adaptive changes of glutathione metabolism in mdx mice are 
likely to lessen the severity and/ or delay the progression of dystrophic disease and 
cardiomyopathy. In fact, Dudley et al.15 have shown that, as compared to age-matched B6 
mice, mdx mice at the age of 14-days before the onset of fiber necrosis demonstrate normal 
glutathione content in tibialis anterior muscles whereas muscle necrosis in 6-8-week-old 
mdx mice is related to a 20% deficiency in glutathione content, occurring despite increased 
GPx activity.15 We also found that glutathione content in gastrocnemius of 20-week-old mdx 
mice was depleted by 33% as compared to B6 mice (0.45 ± 0.06 vs 0.68 ± 0.07 nmol/ mg 
tissue, respectively, p < 0.05, data not shown). This is in keeping with the significant 
muscular weakness experienced by mdx mice from 1 month of age throughout their 
lifespan.50, 51 At the difference from the muscular degenerative process, cardiac involvement 
in mdx mice is usually detected only above 29-weeks of age as an intermediate LV 
hypertrophic stage, prior to the manifestations of contractile dysfunction and dilated 
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cardiomyopathy by the age of 42 weeks.29 We now give evidence that the preservation of 
cardiac structure and function in 20-week-old mdx mice is related to an increased 
expression of cardiac GLCL and GPx1, likely to compensate for increased glutathione 
demand ensuing from exacerbated oxidative challenge. This proposal is supported by the 
finding that BSO-treated mdx mice, which are unable to boost glutathione supply, display an 
earlier onset of cardiac symptoms than untreated mdx mice. Of note, at the dose of BSO 
used, BSO-treated mdx mice have similar glutathione blood level and cardiac content as B6 
mice. Thus BSO treatment essentially impinges on the adaptive increment of glutathione 
synthesis, as further attested by the comparable level of glutathione recycling enzymes 
gene expression in BSO-treated mdx mice and B6 mice.  
The corollary of this statement would be that glutathione supplementation prevents the 
development of cardiomyopathy. As a matter of fact, using a mdx mouse strain that has 
overt cardiac fibrosis, inflammation and abnormalities in cardiomyocyte Ca2+ handling as 
early as the age of 9 weeks, Williams and Allen reported reduced cardiac abnormalities in 
the 9 week-old mice having received oral N- acetylcysteine (NAC), a glutathione precursor, 
from weaning.47 However, before 1 year-old most of the mdx mice from the different strains, 
including ours, display little cardiac pathology.29, 52 The small heart syndrome that we 
identified in our 20-week-old mdx mice has been previously reported in 10-week-old mdx 
mice,53, and typifies patients with chronic fatigue.54, 55 Interestingly, we found that NAC 
treatment (1.4 mg/ 10 g body weight/ day), started from weaning, boosted blood glutathione 
in young mdx mice (but not in older mdx mice with high blood glutathione) and prevented 
the small heart syndrome in 20-week-old mdx mice (not shown).  
From 6 months of age, mdx mice show LV hypertrophy.29, 56 This is representative of 
DMD development since most DMD boys display a hypertrophic stage prior to clinical 
symptoms.35, 57 An important finding of this study is that glutathione deficiency in BSO-
treated mice is associated with LV hypertrophy in 20-week-old mdx mice together with 
diastolic dysfunction, structural and ultrastructural abnormalities. The presence of collapsed 
vessels in BSO-treated mdx mice heart is compatible with compromised vascular supply and 
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cardiomyocyte injury due to ischemia. As a matter of fact, a main ultrastructural alteration in 
the heart of BSO-treated mdx mice consists of mitochondrial abnormalities in 
cardiomyocytes that are considered as stigmatic of oxidative damage.58, 59 The blunting of 
cardiac collagen genes up-regulation in mdx mice treated with BSO, together with the 
appearance of necrosis and inflammation foci, are reminiscent of the increased inflammation 
associated with fibrosis reduction in the diaphragm of mdx mice treated with neutralizing 
antibody against transforming growth factor-beta1.60 This may be indicative of a role of 
collagens in stabilizing the extracellular matrix and cellular membranes in mdx mice heart, 
before the development of fibrosis and subsequent disruption of the cardiac structure.  
In conclusion, firstly, our study show that BSO-treated mdx mice provide a possible 
new experimental model for DMD cardiomyopathy, with defined endpoints (left ventricular 
hypertrophy, diastolic dysfunction, structural abnormalities) that could be used for 
translational studies to test various therapeutic agents. Secondly, our results bring to light an 
adaptive capacity of mdx mice to increase tissue glutathione resource, which faces oxidative 
stress associated with skeletal muscle degeneration/ regeneration cycles and is likely to 
delay dystrophic and cardiac disease progression. Finally, our preliminary insight into the 
glutathione status in DMD patients points out the possible occurrence of systemic 
glutathione deficiency in these patients. This is relevant with the previously reported altered 
glutathione metabolism in DMD fibroblasts.26 One may also note that the degree of 
glutathione deficiency in DMD patients is akin to that previously reported in patients with 
cardiac diseases of non-genetic etiology, whose functional status and structural cardiac 
abnormalities were related to glutathione deficiency.22 Obviously, more investigation is 
needed to prove that glutathione deficiency may determine the progression of the cardiac 
disease in DMD patients. However, these first results encourage further exploring blood 
glutathione status in DMD patients, at different stages of the disease process. In future, this 
might open new therapeutic perspectives with molecules targeting glutathione pathway, 
NAC in particular, which is being launched for the treatment of other inflammatory chronic 
diseases including idiopathic pulmonary fibrosis.61, 62 
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Table 1: Primers used for quantitative RT-PCR 
Gene Primers 
Fragment 
size (bp) 
NCBI reference
GLCLC 
5’ – ATCCTCCAGTTCCTGCACAT–3’ 
5’ – TGTGAATCCAGGGCCTA-3’ 
390 NM_010295.1 
GLCLM 
5’-GCCACCAGATTTGACTGCCTTT-3’ 
5’-CAGGGATGCTTTCTTGAAGAGCTT-3’ 
119 NM_008129.2 
GPX1 
5’-GACTACACCGAGATGAACGA-3’ 
5’-CTTCATTCTTGCCATTCTCCT-3’ 
110 NM_008160.5 
COL1A1 
5’-ACCTGTGTGTTCCCTACTCA-3’ 
5’-GACTGTTGCCTTCGCCTCTG-3’ 
322 NM_007742.2 
COL1A2 
5’-TTAAGACTCAGCCACCCAGA-3’ 
5’-GAGCTGAGTTGCCATTTCCT-3’ 
267 NM_007743.2 
COL3A1 
5’-AATGGTGGTTTTCAGTTCAGC-3’ 
5’-TGGGGTTTCAGAGAGTTTGGC-3’ 
322 NM_009930.1 
COL6A1 
5’-AATTGCCCTGGTCATTACGG-3’ 
5’-CGATAAGCCTTGGCAGGAAA-3’ 
169 NM_009933.3 
18S 
5’-GTAACCCGTTGAACCCCATT-3’ 
5’-CCATCCAATCGGTAGTAGCG-3’ 
151 XO1117 
 
Abbreviations: GLCLC: glutamate-L-cysteine ligase catalytic subunit, GLCLM: 
glutamate-L-cysteine ligase modulatory subunit, GPX1: Glutathione peroxidase 1, COL1A1: 
procollagen type I, alpha 1, COL1A2: procollagen type I, alpha 2, COL3A1: procollagen 
type III, alpha 1, COL6A1: procollagen type VI, alpha 1.
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LEGENDS TO FIGURES 
 
Figure 1. Evolution as a function of age of blood glutathione levels in B6 and 
mdx mice treated or not with BSO. B6 mice received water; mdx mice received either 
water or 5 mM BSO added to the drinking water from 10 to 20 weeks of age. Blood 
glutathione levels were measured at 5, 10, 15 and 20 weeks of age. N= 5 in each group. 
#p < 0.05 vs 5-week-old mdx mice. 
 
Figure 2. Cardiac glutathione levels in 20-week-old B6 and mdx mice treated or 
not with BSO. Glutathione was measured in cardiac samples of 20-week-old B6 and mdx 
mice having received either water or BSO. N=4 to 10 in each group. #p <0.05 vs mdx mice 
receiving water.  
 
Figure 3. Cardiac expression of glutathione recycling enzymes in 20-week-old 
B6 and mdx mice treated or not with BSO. Quantitative real time PCR analysis of 
GLCLC, GLCLM and GPX1 gene expression, encoding glutathione ligase catalytic subunit 
(GLCLC), glutathione ligase modulatory subunit (GLCLM) and glutathione peroxidase 
(GPX1), respectively, in the hearts of 20-week-old B6 and 20- mdx mice having received 
water or BSO. Individual mRNA expression values were normalized relative to 18S mRNA. 
Results are expressed as fold change relative to mean cardiac mRNA expression in B6 
mice. N = 4 to 6 in each group. #p < 0.05 vs B6 mice; †p <0.05 vs untreated mdx mice. 
 
Figure 4. Echocardiography of 20-week-old B6 and mdx mice treated or not with 
BSO. (A) Twenty-week-old B6 and mdx mice have received either water or BSO. BW: body 
weight; HR: heart rate; IVS: intra ventricular septum thickness; LVPW: posterior wall 
thickness; LVEDD: LV end diastolic diameter; iLVEDD: LVEDD indexed to BW; LVM: LV 
mass; iLVM: LVM indexed to BW; LVEF: LV ejection fraction. E/A: ratio between early 
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diastolic filling wave (E) and filling wave due to atrial contraction (A); DcT: E-wave 
deceleration time. #p < 0.05 mdx vs matched B6 group; †P<0.05 BSO mdx vs H2O mdx 
group. (B) LVM in mdx mice, having received water or BSO, was inversely linearly 
correlated with cardiac glutathione content (r = 0.66, p = 0.002). 
 
Figure 5. Sarcolemmal β-dystroglycan immunostaining and cardiac collagen 
gene expression in 20-week-old B6 mice and mdx mice treated or not with BSO. (A) β-
dystroglycan expression around cardiac myocyte membranes is regular in B6 mice and mdx 
mice receiving water, but is destabilized in BSO-treated mdx mice. (B) Quantitative real time 
PCR analysis of COL1A2, COL3A1 and COL6A1 gene coding for 1a2, 3a1 and 6a1 
collagen, respectively, in the hearts of 20-week-old B6 mice and mdx mice having received 
either water or BSO. Individual mRNA expression values were normalized relative to 18S 
mRNA. Results are expressed as fold change relative to mean cardiac mRNA expression in 
B6 mice. N = 4 to 6 in each group. #p < 0.05 vs B6 mice.  
 
Figure 6. Presence of inflammatory micronecrotic foci in the hearts of 20-
week-old BSO-treated mdx mice. (A, B) CD68 immunostaining showing typical foci of 
inflammatory infiltrates. (B) A necrotic cardiomyocyte encircled and phagocytized by 
CD68+ macrophages (original magnification x 400 for both).  
 
Figure 7. Ultrastructural degenerative alterations in the hearts of 20-week-old 
BSO-treated mdx mice. (A) Hearts of 20-week-old mdx mice receiving water display 
normal sarcomere organization illustrated by tightly packed contractile proteins (original 
magnification x 11,500). (B) In contrast, regions of 20-week-old BSO-treated mdx mice 
hearts show cardiomyocytes with cytoplasmic degenerative alterations: intracellular 
amorphous accumulations (asterisks) separating contractile bundles, pronounced 
sarcomere irregularities (Z streaming) (arrow), dilatation of smooth endoplasmic reticulum 
profiles (arrowhead) and giant mitochondria (original magnification x 11,700). 
 27 
 
Figure 8. Vessel associated lesions in the hearts of 20-week-old BSO-treated 
mdx mice. Hearts of 20-week-old BSO-treated mdx mice display a gamut of vessel 
associated lesions. (A). Massive edema (asterisks) and extravasated erythrocytes (arrow) of 
interstitium between 2 cardiomyocytes (arrowheads) (original magnification x 5,600); (B and 
C). Edematous endothelial cells (arrows) accompanied by edema in interstitium and 
neighboring cardiomyocytes (asterisks), incipient in B (original magnification x 7,100) and 
pronounced in C (original magnification x 5,600). (D) A lysing capillary endothelial cell 
characterized by a swollen cytoplasm, (arrowhead), a “ground glass” nucleus (arrow) and a 
reduced lumen (asterisk), and degenerated mitochondria spilling over from surrounding 
cardiomycytes (double arrows), suggesting a focus of micronecrosis (original magnification x 
7 100). 
 
Figure 9. DMD patients may demonstrate systemic glutathione deficiency. Total 
whole blood glutathione was measured in 4 DMD patients on wheelchair dependency (mean 
age of 28 ± 2 years) and in 4 matched healthy volunteers. Three DMD patients displayed 
25% to 40% systemic glutathione deficiency as compared to healthy volunteers. 









